CAR-NK cell therapy for T cell lymphoma and acute myeloid leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have T cell lymphoma or acute myeloid leukemia that has returned or not responded to at least two prior treatments.
- Your cancer cells must have a protein called CD70, found by a lab test.
- You must be between 18 and 75 years old.
- Your overall health must allow for the treatment, with good heart, kidney, and liver function.
- You must not have had a stem cell transplant from a donor recently or have active graft-versus-host disease.
- You must not have other active cancers or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-NK) that targets a protein called CD7 found on some leukemia and lymphoma cells. It may help people whose cancer has not responded to other treatments or has returned.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
This trial tests a new treatment using specially engineered immune cells (CAR-NK cells) that are designed to find and destroy leukemia cells. It may be an option for patients whose leukemia has come back or hasn't responded to other treatments.
Hear when a new Relapsed/Refractory T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.